Ligand id: 7685

Name: mepolizumab

No information available.
Summary of Clinical Use
In November 2015, the US FDA approved mepolizumab for the treatment of severe asthma exacerbations in patients who are already taking other asthma medications [1-2].
In the United States and the European Union, mepolizumab can be used under orphan drug designation for the treatment of Churg-Strauss syndrome and hypereosinophilic syndrome.
To gain full marketing authorisation, mepolizumab is being evaluated in clinical trials in patients with eosinophilic COPD (Phase III), hypereosinophilic syndrome (HES; Phase III) and for eosinophilic granulomatosis with polyangiitis (EGPA or Churg-Strauss Syndrome; Phase III). Click here to view's listing of current mepolizumab trials.
Mechanism Of Action and Pharmacodynamic Effects
Mepolizumab antagonises IL-5 activity by effectively neutralising circulating IL-5. This leads to a reduction in eosinophil numbers in blood, tissue and sputum and this effect underlies the drug's anti-inflammatory action.